Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941

Phase 1 Completed 48 enrolled Astellas Pharma Inc

RandomizedSingle-groupDouble-blindBasic science

Summary

This study determined the safety of ASP1941 after a single and multiple once-daily doses for 10 days in healthy subjects. In addition, the Pharmacokinetics (PK) and Pharmacodynamics (PD) of ASP1941 were assessed.

Timeline

Start: 2007-05
Primary completion: 2008-03
Completion: 2008-03

Publications

Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011 Dec 1;31(12):839-51. doi: 10.1007/BF03256922.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ipragliflozin	Small molecule	5 mg	Oral
Subject	ipragliflozin	Small molecule	600 mg	Oral

Indications

No indication recorded.